Dyadic International, Inc. · NASDAQ:DYAI
Dyadic International — Q1 2026 Earnings Presentation
27 slides from Dyadic International's earnings presentation, May 13, 2026
Slide 1: C1 - CMC Platform
C1 - CMC Platform Rapid, scalable, microbial production platform for animal-free proteins for life sciences, diagnostics, and biomanufacturing. Speed • Yield • Cost • Scalability CMC Presentation WVC - March 2026 1
Slide 2: Safe harbor statement
Safe harbor statement Certain statements contained in this presentation (including any oral commentary that accompanies this presentation) are forward- looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including
Slide 3: C1 Platform Architecture
C1 Platform Architecture An Engineered Fungal Cell Factory for Biologics production Protein Safety and Demonstrated Engineered Fermentation Production Regulatory Product C1 Strain Capability Readiness Diversity Increased Productivity 25 15 g/L 5 -5 Stage Stage Stage Stage 1 2 3 4 Antigen mAb • Stand
Slide 4: The C1 Strain
The C1 Strain Engineered production strain enables efficient production C1 Strain Adaptation C1 Strain Engineering 600 Protease Activity from fermentation cultures >15 protease deletions (w/o CRISPR) 400 < 50x → improved protein yield & stability 200 0 ∆1 ∆4∆4 ∆clr∆5 ∆6 ∆7 ∆8 ∆9 ∆10 ∆11 ∆12 Wild typ
Slide 5: C1 --- Rapid generation of production strains
C1 --- Rapid generation of production strains Plasmid to stable cell lines in as short as ~ 3 weeks1 Workflow Process Scale MTP Ferm., Fermentation Strain Gene Synthesis DSP and from RCB, DNA Construction pre-clinical Sequence and Plasma Analytics and re-isolation DSP, analytics, Construction and RC
Slide 6: C1 Manufacturing Process
C1 Manufacturing Process Rapid, robust, scalable microbial Biomanufacturing process 〉Standard microbial fermentation equipment 〉Low viscosity culture 〉4 to 7 days process 〉Fed batch technology with glucose feeding 〉Industrial scale Single-Use Stainless Steel validated up to >100,000L Upstream Proces
Slide 7: C1 Platform Advantages vs Traditional Systems
C1 Platform Advantages vs Traditional Systems (Doubling Time, Cycle Time, Productivity, No Viral Clearance & Cost) C1 Microbial Feature Mammalian Cells (CHO) Insect Cells (Baculovirus) Platform Cell Doubling Time ~20–24 hr ~18–24 hr ~2.5 hr Cell Line Development ~3–6 months ~3-5 Weeks ~3 weeks Produ
Slide 8: Process Performance
Process Performance - C1 – a rapid, high productivity and flexible platform Faster than other High Yield1 Supports expression of complex eukaryotic expression (4-7 days) structures systems 1 Increased Productivity 25 Trimers 15 g/L 5 -5 Stage Stage Stage Stage 1 2 3 4 Ferritin Antigen mAb Nanopartic
Slide 9: Platform Safety & Regulatory Readiness
Platform Safety & Regulatory Readiness Established safety profile Regulatory and Clinical C1 Host Safety Manufacturing Control Experience • Non-pathogenic filamentous • Controlled impurity profile • Evaluated in nonclinical fungus (HCP, β-glucans, residual DNA) studies • Widely used in industrial *C
Slide 10: Product expression comparable to CHO
Product expression comparable to CHO Flexible expression system for vaccines and therapeutic proteins. C1 RSV trimers with CHO-like structure superior neutralization vs insect systems. C1 mAbs Comparable Neutralization & Binding Comparable immunogenicity, neutralization & binding across diverse biol
Slide 11: Product expression versatility across wide range of molecules
Product expression versatility across wide range of molecules Flexible expression system for vaccines and therapeutic proteins. C1 human mAbs provides protection against SARS- CoV-2 in hamster and non- human primate models Full Spike from C1 Full Spike from CHO C1 spike protein of the SARS-CoV-2 bin
Slide 12: Backup slides
Backup slides CMC Presentation- March 2026
Slide 13: RSV/hMPV/PIV triple combination in pre-clinical
RSV/hMPV/PIV triple combination in pre-clinical Structure-guided prefusion antigens rapidly produced • Respiratory viruses cause major using C1 fermentation global disease burden, including: • Respiratory Syncytial Virus (RSV) • Human Metapneumovirus (hMPV) • Parainfluenza Virus (PIV3) • Currently n
Slide 14: RSV/hMPV/PIV respiratory product produced in C1
RSV/hMPV/PIV respiratory product produced in C1 Rapid, High Yield, and Immunogenic RSV PreF antigen C1 RSV trimers with CHO-like structure Yield is ~ 1.7g/L in 7 days superior neutralization vs insect systems. CHO Structural Validation: Week-5 Neutralization Results: • High expression in C1 • All va
Slide 15: Decades of innovation, now driving scalable growth
Decades of innovation, now driving scalable growth Evolving customer demands… ✓ Drug Supply chain safety & security A platform with proven market validation ✓ Ethical concerns – animal free ✓ Health and safety 1990s 2015 2022 2025+ ✓ Environmental sustainability …align with recombinant advantages ✓
Slide 16: Why C1 microbial fermentation matters
Why C1 microbial fermentation matters C1 enables significantly faster development timelines while maintaining CHO-like protein structure and functionality, supporting rapid response for vaccine and biologics manufacturing. CHO: C1 Example: • Long cell line development timelines • RSV Prefusion Trime
Slide 17: Human Glyco Pattern
Human Glyco Pattern C1 Wild type glyco pattern targets are man3 to man9. DNA + Host Strain (Empty) • Our aim has been to humanize N-glycosylation pathway and (containing humanized (target) enable its use as production host for pharmaceutical proteins glycan machinery) that require humanized glycans
Slide 18: Multiple approaches to improve C1 productivity
Multiple approaches to improve C1 productivity (6–8× productivity improvements demonstrated) Folding and secretion Fermentation Combinatorial library library optimization Promoters UPS Signal Sequences Codon optimized CDSs Terminators 1 2 3 4 5 … N Several building blocks are being assembled using a
Slide 19: Comparability between Tox GLP and Phase I GMP batches
Comparability between Tox GLP and Phase I GMP batches Quality by Design for C1-produced antigens Comparability of DYAI-100 vaccine candidate batches GLP vs. Phase I GMP for some CQAs Attribute GLP GMP Comparability Concentration 1.66 mg/ml 1.70 mg/ml confirmed Potency (ELISA - IVRP) 100 % (standard)
Slide 20: Successful DYAI-100 Phase 1 Results: Primary Endpoint Achieved
Successful DYAI-100 Phase 1 Results: Primary Endpoint Achieved Phase 1 Study Results: Clinical safety demonstrated in humans ▪ Double blind placebo-controlled safety study of 30 healthy adults conducted in South Africa. ▪ Primary endpoint of the study was to demonstrate the safety and reactogenicity
Slide 21: Global Validation, CEPI, Gates Foundation, EU Vaccine Hub
Global Validation, CEPI, Gates Foundation, EU Vaccine Hub Advancing Pandemic Preparedness with FBS leveraging C1 CEPI/EU Vaccine Hub 〉 Building on Dyadic’s C1 platform and recent scientific advances 〉 Leveraging major new funding: • CEPI $4.5M • EU Vaccine Hub/FBS (€170M) • Gates Foundation mAbs $3M
Slide 22: Rapid Response Biomanufacturing Capability
Rapid Response Biomanufacturing Capability Gene Sequence → Purified Antigen or mAb in ~33 Days Accelerated Development Timeline Validated in Real-World Programs: 〉 Design & Synthesis • CEPI / EU Vaccine Hub aligned programs • Applied to preclinical H5 avian influenza 〉 Strain Development candidates
Slide 23: $3 Million Gates Foundation Grant to Develop Cost-Effective mAbs
$3 Million Gates Foundation Grant to Develop Cost-Effective mAbs C1- Helping to Democratize mAbs; Multi-gram per liter monoclonal antibody production ➢ 12 g/l in 7-day fermentation after single transformation, prior to future optimization ➢ ~ 100 % Human Glycan structures ➢ Released N-glycans of sin
Slide 24: RSM01 mAb Potency Test – C1 Cells Are Equivalent to CHO Cells
RSM01 mAb Potency Test – C1 Cells Are Equivalent to CHO Cells BLI Sensor Kinetics of Respiratory Syncytial Virus (RSV) Plaque-Reduction Neutralization Antigen Test (PRNT) on Vero cells. The test was done against various RSV strains (RSV A2, RSV A-Long, and RSV Antiboy B). Two different versions of C
Slide 25: C1 mAbs Show Comparable Neutralization & Binding to CHO
C1 mAbs Show Comparable Neutralization & Binding to CHO SARS-COV2 ZIKA 125 % Neutralization of SARS-CoV2_rVSV 100 IC50 ng/ml 75 414-6 207 416-6 306 50 415-6 175 417-5 278 25 CHO-2381 311 r2D22 0 1 2 3 4 -25 mAb conc log10 ( ng/mL) ANDES VIRUS RIFT VALLEY % Infection relative to no mAb control RVFV-2
Slide 26: C1; a Safe, Efficient, Affordable & Sustainable Biomanufacturing
Advancing C1 Platform & Product Candidates C1 platform enables gram-per-liter yields in 4–7 days, supporting faster development, manufacturing, and release—with CHO-like quality but higher yield, lower C1; a Safe, Efficient, cost, and no viral clearance. Affordable & Sustainable Advancing an expandi
Slide 27: Thank You
Thank You ir@dyadic.com Nasdaq:DYAI